Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

Cancer chemotherapy and pharmacology - 1 Oct 2011

Park Jin Hyun, Han Sae-Won, Oh Do-Youn, Im Seock-Ah, Jeong Seung-Yong, Park Kyu Joo, Kim Tae-You, Bang Yung-Jue, Park Jae-Gahb

Abstract excerpt

PURPOSE: The aim of this study was to determine the expression of molecular markers in metastatic colorectal cancer (mCRC) and the concordance between primary tumor and metastasis. We also aimed to determine the relationship between molecular markers and clinical outcomes of cetuximab-containing chemotherapy. METHODS: Seventy-five mCRC patients who received cetuximab-containing chemotherapy between 2000 and 2008...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to PTEN Phosphohydrolase

Share to ras Proteins

Share to Receptor, IGF Type 1

Source

Identifiers

PMID: 21340604
DOI: 10.1007/s00280-011-1586-z

Genes

EGFR
BRAF
KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.PMID 21340604Read ↗

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.Semantic proximity Read ↗

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.Semantic proximity Read ↗

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.Semantic proximity Read ↗

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.Semantic proximity Read ↗

Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.Semantic proximity Read ↗

Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.Semantic proximity Read ↗

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.Semantic proximity Read ↗

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.Semantic proximity Read ↗

Biomarker concordance between primary colorectal cancer and ovarian metastases: a Dutch cohort study.Semantic proximity Read ↗

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.Semantic proximity Read ↗

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.Semantic proximity Read ↗

Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.